Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Lung Neoplasms × X-Rays × Clear all

Phase

Status

Sponsor Class

OTHER 18 NIH 7 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1 Opioid-Related Disorders 1 Lymphoma, Follicular 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Barrett Esophagus 1

Interventions

Carboplatin 97 Pemetrexed 70 pembrolizumab 68 Cisplatin 59 Paclitaxel 54 Docetaxel 45 Gemcitabine 37 Erlotinib Hydrochloride 24 Nivolumab 23 osimertinib 17 Bevacizumab 17 durvalumab 14 Cetuximab 13 130-nm albumin-bound paclitaxel 13 Gefitinib 11 Drug Therapy 11 Etoposide 10 Ipilimumab 9 Injections 9 Albumin-Bound Paclitaxel 9 Vinorelbine 8 Radiotherapy 8 motexafin gadolinium 7 capmatinib 7 epacadostat 6 atezolizumab 6 Taxes 6 Cyclophosphamide 6 vandetanib 5 entinostat 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07499674 2026-03-30

VISUALIZE-2

Vergent Bioscience, Inc.

Phase 3 Recruiting

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡